These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

822 related articles for article (PubMed ID: 20156971)

  • 1. Tumor-reactive CD4(+) T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts.
    Quezada SA; Simpson TR; Peggs KS; Merghoub T; Vider J; Fan X; Blasberg R; Yagita H; Muranski P; Antony PA; Restifo NP; Allison JP
    J Exp Med; 2010 Mar; 207(3):637-50. PubMed ID: 20156971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Naive tumor-specific CD4(+) T cells differentiated in vivo eradicate established melanoma.
    Xie Y; Akpinarli A; Maris C; Hipkiss EL; Lane M; Kwon EK; Muranski P; Restifo NP; Antony PA
    J Exp Med; 2010 Mar; 207(3):651-67. PubMed ID: 20156973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Suppression of T-cell expansion by melanoma is exerted on resting cells.
    Russ AJ; Wentworth L; Xu K; Rakhmilevich A; Seroogy CM; Sondel PM; Suresh M; Cho CS
    Ann Surg Oncol; 2011 Dec; 18(13):3848-57. PubMed ID: 21465311
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Increased frequency of suppressive regulatory T cells and T cell-mediated antigen loss results in murine melanoma recurrence.
    Jensen SM; Twitty CG; Maston LD; Antony PA; Lim M; Hu HM; Petrausch U; Restifo NP; Fox BA
    J Immunol; 2012 Jul; 189(2):767-76. PubMed ID: 22723522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-avidity autoreactive CD4+ T cells induce host CTL, overcome T(regs) and mediate tumor destruction.
    Brandmaier AG; Leitner WW; Ha SP; Sidney J; Restifo NP; Touloukian CE
    J Immunother; 2009 Sep; 32(7):677-88. PubMed ID: 19561540
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of effector cell-derived IL-4, IL-5, and perforin in early and late stages of type 2 CD8 effector cell-mediated tumor rejection.
    Dobrzanski MJ; Reome JB; Dutton RW
    J Immunol; 2001 Jul; 167(1):424-34. PubMed ID: 11418679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Divergent roles for CD4+ T cells in the priming and effector/memory phases of adoptive immunotherapy.
    Hu HM; Winter H; Urba WJ; Fox BA
    J Immunol; 2000 Oct; 165(8):4246-53. PubMed ID: 11035058
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Costimulation of tumor-reactive CD4+ and CD8+ T lymphocytes by B7, a natural ligand for CD28, can be used to treat established mouse melanoma.
    Li Y; McGowan P; Hellström I; Hellström KE; Chen L
    J Immunol; 1994 Jul; 153(1):421-8. PubMed ID: 7515929
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human telomerase reverse transcriptase-transduced human cytotoxic T cells suppress the growth of human melanoma in immunodeficient mice.
    Verra NC; Jorritsma A; Weijer K; Ruizendaal JJ; Voordouw A; Weder P; Hooijberg E; Schumacher TN; Haanen JB; Spits H; Luiten RM
    Cancer Res; 2004 Mar; 64(6):2153-61. PubMed ID: 15026357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The duration of TCR/pMHC interactions regulates CTL effector function and tumor-killing capacity.
    Riquelme E; Carreño LJ; González PA; Kalergis AM
    Eur J Immunol; 2009 Aug; 39(8):2259-69. PubMed ID: 19637198
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tumor-Unrelated CD4 T Cell Help Augments CD134 plus CD137 Dual Costimulation Tumor Therapy.
    Mittal P; St Rose MC; Wang X; Ryan JM; Wasser JS; Vella AT; Adler AJ
    J Immunol; 2015 Dec; 195(12):5816-26. PubMed ID: 26561553
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetically modified dendritic cells prime autoreactive T cells through a pathway independent of CD40L and interleukin 12: implications for cancer vaccines.
    Wan Y; Bramson J; Pilon A; Zhu Q; Gauldie J
    Cancer Res; 2000 Jun; 60(12):3247-53. PubMed ID: 10866318
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective expansion of a specific anti-tumor CD8+ cytotoxic T lymphocyte clone in the bulk culture of tumor-infiltrating lymphocytes from a melanoma patient: cytotoxic activity and T cell receptor gene rearrangements.
    Gervois N; Heuze F; Diez E; Jotereau F
    Eur J Immunol; 1990 Apr; 20(4):825-31. PubMed ID: 1971794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD8+ T cell immunity against a tumor/self-antigen is augmented by CD4+ T helper cells and hindered by naturally occurring T regulatory cells.
    Antony PA; Piccirillo CA; Akpinarli A; Finkelstein SE; Speiss PJ; Surman DR; Palmer DC; Chan CC; Klebanoff CA; Overwijk WW; Rosenberg SA; Restifo NP
    J Immunol; 2005 Mar; 174(5):2591-601. PubMed ID: 15728465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of melanoma growth after treatment with dendritic cells in a Tyr-SV40E murine model requires CD4+ T cells but not CD8+ T cells.
    Milling SW; Sai T; Silvers WK; Mintz B
    Melanoma Res; 2004 Dec; 14(6):555-62. PubMed ID: 15577330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adoptive transfer of ex vivo-activated memory T-cell subsets with cyclophosphamide provides effective tumor-specific chemoimmunotherapy of advanced metastatic murine melanoma and carcinoma.
    Gold JE; Zachary DT; Osband ME
    Int J Cancer; 1995 May; 61(4):580-6. PubMed ID: 7759164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interferon γ limits the effectiveness of melanoma peptide vaccines.
    Cho HI; Lee YR; Celis E
    Blood; 2011 Jan; 117(1):135-44. PubMed ID: 20889921
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25(+) regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses.
    Sutmuller RP; van Duivenvoorde LM; van Elsas A; Schumacher TN; Wildenberg ME; Allison JP; Toes RE; Offringa R; Melief CJ
    J Exp Med; 2001 Sep; 194(6):823-32. PubMed ID: 11560997
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Specific CD4
    Liu Q; Wang L; Lin H; Wang Z; Wu J; Guo J; Wen S; Ran L; Yue Z; Su X; Wu Q; Tang J; Li Z; Hu L; Xu L; Ye L; Huang Q
    Front Immunol; 2022; 13():875718. PubMed ID: 35784297
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined Photosensitization and Vaccination Enable CD8 T-Cell Immunity and Tumor Suppression Independent of CD4 T-Cell Help.
    Varypataki EM; Hasler F; Waeckerle-Men Y; Vogel-Kindgen S; Høgset A; Kündig TM; Gander B; Halin C; Johansen P
    Front Immunol; 2019; 10():1548. PubMed ID: 31333674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.